Cloning from Insulinoma Cells of Synapsin I Associated with Insulin Secretory Granules*

Kazuya MatsumotoDagger §, Kenji EbiharaDagger §, Hideyuki YamamotoDagger , Hirotaka TabuchiDagger §, Kohji FukunagaDagger , Michio Yasunami, Hiroaki Ohkubo, Motoaki Shichiri§, and Eishichi MiyamotoDagger parallel

From the Departments of Dagger  Pharmacology and § Metabolic Medicine, and the  Institute of Molecular Embryology and Genetics, Kumamoto University School of Medicine, Kumamoto 860-0811, Japan

    ABSTRACT
Top
Abstract
Introduction
References

Synapsin I is a synaptic vesicle-associated protein involved in neurotransmitter release. The functions of this protein are apparently regulated by Ca2+/calmodulin-dependent protein kinase II (CaM kinase II). We reported evidence for CaM kinase II and a synapsin I-like protein present in mouse insulinoma MIN6 cells (Matsumoto, K., Fukunaga, K., Miyazaki, J., Shichiri, M., and Miyamoto, E. (1995) Endocrinology 136, 3784-3793). Phosphorylation of the synapsin I-like protein in these cells correlated with the activation of CaM kinase II and insulin secretion. In the present study, we screened the MIN6 cDNA library with the full-length cDNA probe of rat brain synapsin Ia and obtained seven positive clones; the largest one was then sequenced. The largest open reading frame deduced from the cDNA sequence of 3695 base pairs encoded a polypeptide of 670 amino acids, which exhibited significant sequence similarity to rat synapsin Ib. The cDNA contained the same sequence as the first exon of the mouse synapsin I gene. These results indicate that synapsin Ib is present in MIN6 cells. Synapsin I was expressed in normal rat islets, as determined by reverse transcriptase-polymerase chain reaction analysis. Immunoblot analysis after subcellular fractionation of MIN6 cells demonstrated that synapsin Ib and delta  subunit of CaM kinase II co-localized with insulin secretory granules. By analogy concerning regulation of neurotransmitter release, our results suggest that phosphorylation of synapsin I by CaM kinase II may induce the release of insulin from islet cells.

    INTRODUCTION
Top
Abstract
Introduction
References

Intracellular Ca2+ has been reported to play a critical role in insulin secretion. Glucose seems to elevate intracellular Ca2+ concentrations via influx through voltage-dependent Ca2+ channels. The Ca2+ influx primarily occurs as a result of the membrane depolarization secondary to closure of ATP-sensitive K+ channels (1-3). After elevation of intracellular Ca2+ levels, effector molecules are activated; these include calmodulin (CaM)1 and protein kinase C. CaM is a ubiquitous Ca2+-binding protein and may be involved in a variety of Ca2+-mediated processes. In fact, glucose-stimulated insulin secretion is inhibited by CaM antagonists in rat pancreatic islet cells (4). One of the primary effectors of CaM is Ca2+/CaM-dependent protein kinase. Myosin light chain kinase is reported to be involved in insulin secretion (5). Myosin light chain kinase phosphorylates the myosin light chain, and activation of the actin-activated Mg2+-ATPase is considered to be involved in the movement of secretory granules (1). Other Ca2+/CaM-dependent protein kinases have been identified in rat pancreatic islets (6, 7), and one of the kinases has kinetic properties similar to Ca2+/CaM-dependent protein kinase II (CaM kinase II) (7). Indeed, the immunoreactivity of CaM kinase II was detected in rat pancreatic islets when a specific CaM kinase II antibody was used (8). CaM kinase II inhibitors such as KN-62 (9, 10) and KN-93 (5) inhibit glucose-induced insulin secretion from insulinoma cells and rat pancreatic islets. Moreover, an inhibitory peptide of this enzyme attenuated the Ca2+-induced exocytosis in single beta cells (11). CaM kinase II in isolated islets (12) and mouse insulinoma cells (13) was activated with glucose. The activation of CaM kinase II was reported to occur in the initial phase and also in the second phase of glucose-stimulated insulin secretion (14). These findings suggest a role for CaM kinase II in glucose-induced insulin secretion.

We reported that inhibition of calcineurin by the specific inhibitor, cyclosporin A, enhances the glucose- and tolbutamide-stimulated insulin secretion from MIN6 cells with stimulation of synapsin I-like protein phosphorylation (15). These findings suggested that insulin secretion from MIN6 cells is regulated by CaM kinase II and protein phosphatase with a concomitant phosphorylation of synapsin I-like protein.

To better understand the physiological roles of CaM kinase II in insulin secretion, investigation should focus on the endogenous substrate(s) for CaM kinase II. One of the most attractive candidates for substrates involved in stimulus-secretion coupling is synapsin I (16, 17). Synapsin I is a family member of proteins highly specific to nerve terminals and comprises four homologous proteins, synapsin Ia and Ib and synapsin IIa and IIb. Synapsin Ia and Ib were discovered as endogenous substrates for cyclic AMP- and Ca2+-dependent protein kinases and were subsequently found to be synaptic vesicle-associated proteins. They appear to play key roles in structural organization of the presynaptic compartment and in regulation of neurotransmitter release. The dephosphorylated form of synapsin I binds to synaptic vesicles with a high affinity. The phosphorylation of synapsin I by CaM kinase II results in removal of the inhibition of the interaction between synaptic vesicles and plasma membranes and thereby induces concomitant changes in Ca2+-dependent neurotransmitter release.

We reported elsewhere the existence of CaM kinase II and its endogenous substrate, an 84-kDa protein in mouse insulinoma MIN6 cells (13). As the 84-kDa protein had several biochemical and immunochemical properties in common with synapsin I, we tentatively termed it a "synapsin I-like protein." To clarify whether or not the synapsin I-like protein is a new isoform of synapsin I expressed in endocrine cells, we isolated and sequenced the cDNA clones that hybridized to rat brain synapsin I cDNAs from a cDNA library of MIN6 cells. Sucrose density gradient fractionation of MIN6 cells revealed that the protein and delta  subunit of CaM kinase II (CaM kinase II delta ) co-localizes with insulin secretory granules. We also found that the protein is present in other endocrine cells.

    EXPERIMENTAL PROCEDURES

Materials-- The following chemicals and reagents were obtained from the indicated sources: Dulbecco's modified Eagle's medium, Nissui Pharmaceutical Co. (Tokyo, Japan); RPMI 1640 medium, Life Technologies, Inc.; fetal bovine serum, JRH Biosciences (Lenexa, KS); [alpha -32P]dCTP, Amersham Pharmacia Biotech (Tokyo, Japan); [gamma -32P]ATP and 125I-protein A, NEN Life Science Products; bovine serum albumin, the antibody against synaptophysin (monoclonal), and mouse IgG (polyclonal), Sigma; (p-amidinophenyl)methanesulfonyl fluoride hydrochloride, Wako Pure Chemical Industries (Osaka, Japan); MES, Dojindo Laboratories (Kumamoto, Japan); Phadeseph Insulin, Kabi Pharmacia Diagnostics (Uppsala, Sweden). Polyclonal antibody (IgG fractions) against synapsin I was prepared as described (18). The polyclonal antibody against carboxyl-terminal peptide derived from the delta 1 to delta 4 isoforms of CaM kinase II delta  was prepared. The preparation and characterization of the antibody will be described elsewhere.2 The polyclonal antibody against chromogranin A was a generous gift of Dr. N. Yanagihara (University of Occupational and Environmental Health) (19). All other chemicals and reagents were of analytical grade.

Cell Culture-- MIN6 cells, alpha TC-6 cells, and AtT-20 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 25 mM glucose, 50 IU of penicillin/ml, 50 µg of streptomycin/ml, 5 µM 2-mercaptoethanol, and 15% heat-inactivated fetal bovine serum, as described (20-22). Hamster insulinoma In-R1-G9 cells and HIT-T15 cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 IU of penicillin/ml, and 100 mg of streptomycin/ml (23). Bovine adrenal chromaffin cells were kindly provided by Dr. N. Yanagihara (19).

Northern Blot Analysis-- Total RNA was prepared from rat brain, mouse brain (C57BL/6), and MIN6 cells as described (24). Rat synapsin Ia and Ib cDNAs were kindly provided by Dr. P. Greengard (Rockefeller University). For RNA transfer blots, 5, 5, and 20 µg of total RNAs from rat and mouse brains and MIN6 cells, respectively, were denatured with formaldehyde, electrophoresed on a 1% agarose gel, and transferred to a nylon membrane. Following overnight hybridization, the membranes were washed once in each of the following solutions prior to autoradiography: (a) 2× SSC, 0.1% SDS for 10 min; (b) 1× SSC, 0.1% SDS for 10 min; and (c) 1× SSC, 0.1% SDS for 1 h at 65 °C and exposed to x-ray film.

Isolation of cDNA Clones-- About 1.1 × 105 independent lambda Zap phage clones of the mouse insulinoma MIN6 cDNA library, kindly provided by Dr. H. Ishihara (University of Tokyo) (25), were screened with the full-length fragment of the cDNA-encoding rat brain synapsin Ia as a probe. The probe was labeled with [alpha -32P]dCTP to a specific activity of 2.9 × 109 cpm/µg with the Random Primer Kit (Takara Biomedicals), as described by the manufacturer. The plaque hybridization assay was performed in 0.9 M NaCl, 50 mM NaH2PO4, 5 mM EDTA (pH 7.7), 0.1% bovine serum albumin, 0.1% Ficoll 400, 0.1% polyvinylpyrrolidone, and 0.1% SDS in the presence of 100 µg/ml denatured herring DNA at 65 °C. The final wash of membranes was carried out in 0.15 M NaCl, 15 mM sodium citrate, and 0.1% SDS at 60 °C for 60 min. The pBluescript SK(-) phagemids containing cDNA inserts were recovered from purified positive phage clones following the procedures outlined in the Rapid Excision Kit (Stratagene, La Jolla, CA).

DNA Analyses-- The nucleotide sequence was determined using the DyeDeoxyTM Terminator Cycle Sequencing Kit or PRISM Sequenase® Terminator Double-Stranded DNA Sequencing Kit and model 373S DNA sequencer (Applied Biosystems Japan, Chiba, Japan).

Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Analysis-- Islets were isolated by collagenase digestion from the pancreas of Wistar rats, as described (26). Although the preparation of islets would contain non-beta cells, they would be less than 10-20% of all the islet cell population, as described (27, 28). Therefore, more than 80% would be beta cells. Total cellular RNA was extracted from isolated islets using a TriZOL Total RNA Isolation Kit (Life Technologies, Inc.), according to the manufacturer's protocol. The total RNA was reverse-transcribed using an oligo(dT) primer (Promega) and Moloney murine leukemia virus transcriptase (Life Technologies, Inc.). Primers used for the cDNA synthesis were designed to span alternatively spliced fragments thereby allowing size discrimination between synapsin Ia and Ib. Primers used to amplify synapsin I cDNA were 5'-AGGCTACCCGTCAGGCATCTATCTC-3' and 5'-TCACCTCATCCTGGCTAAGG-3' (nucleotides 1759-1783 and 2120-2139, a 380-base pair fragment of synapsin Ia or nucleotides 1759-1783 and 2082-2101, a 342-base pair fragment of synapsin Ib) (29). PCR amplification consisted of a 5-min start at 95 °C, followed by 35 cycles at 95 °C for 45 s, 65 °C for 45 s, 72 °C for 2 min, and a final cycle at 72 °C for 5 min. For sequencing of PCR products, each PCR fragment was purified by agarose gel electrophoresis and ligated into the pCRTMII cloning vector following procedures outlined in the original TA Cloning Kit (Invitrogen, Carlsbad, CA).

Equilibrium Sucrose Density Gradients-- MIN6 cells grown in ten 100-mm dishes to 90% confluency were harvested by trypsinization, pelleted by centrifugation, resuspended in 5 volumes of the homogenizing buffer (0.25 M sucrose, 10 mM EDTA, 10 mM MES (pH 6.5), 1 mM (p-amidinophenyl)methanesulfonyl fluoride hydrochloride, 0.1 mM leupeptin, 75 µM pepstatin A, and 0.1 mg of aprotinin/ml), and homogenized in a Teflon glass homogenizer. The homogenate was centrifuged at 6000 × g at 4 °C for 10 min, and the resulting supernatant was loaded onto the top of a continuous sucrose density gradient (0.5-2 M sucrose, 10 mM EDTA, and 10 mM MES, pH 6.5) and then centrifuged at 100,000 × g at 4 °C for 6 h in a swing rotor (RPS55T-2, Hitachi Koki Co., Katsuta, Ibaraki, Japan) (30). Fractions (300 µl each) were collected from the top of the gradient and used for immunoblot analysis and the insulin assay. Insulin content in each fraction was determined using the insulin assay kit (Phadeseph Insulin).

Preparation of the Cytosol and Particulate Fractions from Various Cultured Cells and Freshly Obtained Bovine Adrenal Medulla-- The cells and tissue of bovine adrenal medulla were homogenized with 5 volumes of 20 mM Tris-HCl (pH 7.5), 4 mM EGTA, 4 mM EDTA, 1 mM dithiothreitol, 0.1 mM leupeptin, 75 µM pepstatin A, and 0.1 mg of aprotinin/ml. The homogenate was centrifuged at 16,350 × g for 20 min at 4 °C using a desk top centrifuge. The resulting supernatant was used as the crude cytosol fraction. The pellet was homogenized with 5 volumes of 50 mM HEPES (pH 7.5), 0.1% Triton X-100 (v/v), 4 mM EGTA, 10 mM EDTA, 30 mM sodium pyrophosphate, 200 mM beta -glycerophosphate, 50 mM sodium fluoride, and protease inhibitors described above and centrifuged at 16,350 × g for 20 min. The resulting supernatant served as the crude particulate fraction.

    RESULTS

Isolation and Characterization of Synapsin I cDNA from MIN6 Cells-- In foregoing work, we identified the synapsin I-like protein in MIN6 cells (13). If the protein is an isoform of synapsin I expressed in insulinoma cells, cDNA probes corresponding to full-length nucleotides of synapsin Ia or Ib could hybridize to the mRNA of the protein. In fact, we noted the expression of 3.7-kilobase mRNA in MIN6 cells by Northern blot analysis with either cDNA probe (Fig. 1). No other mRNA bands were detected, even under conditions of low stringency (data not shown). Because the synapsin I-like protein is the major protein that immunoreacted with the anti-synapsin I antibody (13), it seemed plausible that the synapsin I-like protein originated from the 3.7-kilobase mRNA. To clarify this point, we cloned the cDNA that hybridized with rat synapsin I cDNA.


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 1.   Northern blot analysis of mRNA of synapsin I in MIN6 cells. Total RNA from MIN6 cells (20 µg) and mouse and rat brains (5 µg each) was separated on a 1% agarose gel, transferred to a nylon membrane, and hybridized with a 32P-labeled cDNA probe derived from rat brain synapsin Ia or Ib. Size markers used were rat ribosomal RNAs of 18 and 28 S.

Approximately 1.1 × 105 independent lambda Zap phage clones from a cDNA library of MIN6 cells were screened with the 32P-labeled synapsin Ia cDNA probe, and seven positive clones were obtained. The cDNA inserts from these clones were further characterized by restriction mapping analysis and partial sequence determination of their 5'-ends. One of these clones, designated sim5, contained a full-length open reading frame and was further analyzed (Figs. 2 and 3). The largest open reading frame deduced from the 3695-base pair sequence of the sim5 cDNA encoded a polypeptide of 670 amino acids, which exhibited a significant sequence similarity to rat synapsin Ib (97.8% identity). All seven serine residues phosphorylated in bovine (31, 32), rat, and human synapsin I are present in the mouse sequence (Fig. 2). Furthermore, sim5 contained a nucleotide sequence identical to the first exon of mouse brain synapsin I gene (33) (Fig. 3A). Thus, we concluded that sim5 originated from the gene that encodes mouse brain synapsin I. Eleven amino acids were different from rat brain synapsin Ib, and three additional amino acids (Gln421, Pro422, and Thr601) were observed in the synapsin Ib of MIN6 cells.


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 2.   Comparison of the deduced amino acid sequence of sim5 with that of rat synapsin Ib. Sequences are given in single letter code. Residues that are identical in the rat synapsin Ib (RatIb) (29) to those of sim5 are indicated by asterisks. Dashes denote gaps. Seven vertical arrows above serine residues mark the sequenced phosphorylation sites in rat synapsin I.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 3.   Analyses of clones of synapsin I obtained from MIN6 cDNA library. A, comparison of the nucleotide sequences of sim5 with those of the first exon from mouse synapsin I (m.synI) (31). B, comparison of the nucleotide sequence of sim2 with those of sim5, rat synapsin Ia (Syn Ia), and rat synapsin Ib (Syn Ib) (29). The sim2 clone contains 38-base nucleotides deleted by alternative splicing in mRNA of rat synapsin Ib.

In neuronal cells, the primary transcript of the synapsin I gene was alternatively spliced, and two isoforms, Ia and Ib, were generated (29). These two isoforms differed in their carboxyl termini, and this alternative splicing mechanism was reported to be conserved well among human, rat, and bovine cells (17). In addition to the synapsin I-like protein, an autoradiograph of the immunoblot analysis showed another faint band at position ~88 kDa on SDS-polyacrylamide gel electrophoresis after long exposure to the x-ray film (data not shown). Therefore, we investigated the possibility that synapsin Ia might be present in MIN6 cells. Using primers spanning the splice acceptor site on the primary RNA transcript, we found that one clone designated sim2 had 38 nucleotides that were not present in rat brain synapsin Ib mRNA (Fig. 3B). The 38 nucleotides were the same as those expressed in rat brain synapsin Ia. sim2 did not contain the complete open reading frame of synapsin Ia, yet when the 38 nucleotides were inserted into the sim5 sequence and transferred to amino acids, the sequence homology between rat brain synapsin Ia and the putative full-length sim2 transcript was 94.2% (data not shown). These results strongly suggest that the mRNA of mouse synapsin Ia is also expressed in MIN6 cells.

Expression of Synapsin I mRNA in Rat Isolated Islets-- To determine whether rat pancreatic islets express synapsin Ia and/or Ib, we prepared total RNA from rat islets. When the total RNA from MIN6 cells and rat islets was subjected to RT-PCR, two amplified products were obtained (Fig. 4). When PCR amplification was performed without reverse transcriptase reaction, these two bands were not detected. When genomic DNA from rat liver was used as a template, an approximately 1330-base pair band was amplified. All three products hybridized with the synapsin Ib cDNA probe (data not shown). These observations mean that the former two products were not amplified from genomic DNA. When we subcloned the two products for sequencing, we confirmed that they were the predicted fragments of synapsin Ia and Ib (data not shown).


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 4.   Expression of synapsin I mRNA in normal rat islets. Total RNA extracted from MIN6 cells or isolated rat islets was subjected to RT-PCR as described under "Experimental Procedures." The genomic DNA from rat liver was subjected to PCR. The PCR products were separated on a 0.8% agarose gel and were visualized by the use of ethidium bromide. SynIs, synapsins I.

Co-localization of Synapsin I, CaM Kinase II delta , and Secretory Granules in MIN6 Cells-- In neuronal cells, peptide and nonpeptide neurotransmitters are packed in large density core vesicles and synaptic vesicles, respectively, and synapsin I was reported to be associated with synaptic vesicles rather than large density core vesicles (34). Large density core vesicles were considered to be counterparts of the secretory granules in endocrine cells. In addition to insulin secretory granules, islet beta cells were seen to have synaptic vesicle-like microvesicles, which contain gamma -aminobutyric acid and glutamic acid decarboxylase (35). From these data, we considered the possibility that synapsin I in MIN6 cells is associated with microvesicles but not with insulin secretory granules. We then carried out equilibrium sedimentation through a linear 0.5-2.0 M sucrose gradient using the MIN6 cell extracts (Fig. 5). Individual fractions were collected, and immunoblot analysis was done with antibodies against synapsin I, synaptophysin, chromogranin A, and CaM kinase II delta . The insulin secretory granule fraction was identified based on measurements of immunoreactive insulin. Fig. 5 summarizes the results of one of four independent experiments. Synapsin I was present in relatively dense fractions, and synaptophysin, a marker for endosomes and small density vesicles, was mainly observed in distinct membrane fractions from synapsin I. A minor peak of synaptophysin was also observed in the insulin secretory granule fraction. Moreover, most of the immunoreactive insulin (Fig. 5B) and the immunoreactivity of chromogranin A, a marker for large secretory granules (36) (data not shown) and CaM kinase II delta , were detected in the same fractions as synapsin I. Thus, synapsin I was co-fractionated with insulin secretory granules in MIN6 cells. Co-localization of synapsin I with insulin secretory granules was observed in an independent beta cell line, HIT-T15 cells (data not shown).


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 5.   Co-fractionation of synapsin I and CaM kinase II delta  with secretory granules. A, equal volumes of fraction of MIN6 cells were blotted with polyclonal anti-synapsin I (1:200), monoclonal anti-synaptophysin (1:200), and polyclonal anti-CaM kinase II delta  (1:200) antibodies. The positions of synapsin I (Syn I), synaptophysin (Synapt), and CaM kinase II delta  (KIIdelta ) are indicated. B, top panel, plots of synapsin I (bullet ), synaptophysin (open circle ), and CaM kinase II delta  (black-triangle) immunoreactivity (A) for each fraction. Bottom panel, plots of immunoreactive insulin (IRI) (black-square) determined by radioimmunoassay and protein concentrations () for each fraction. Immunoreactivity was determined using a Bio-image analyzer (BAS 1000, Fuji Film Co.) and normalized to total immunoreactivity summed over all fractions. Fractions were collected from the top of the tube with the first fraction representing the lightest sucrose fraction.

Expression of Synapsin I in Endocrine Cells-- We then asked if synapsin I occurs in other endocrine cells. Fig. 6 shows immunoblot analysis of synapsin I in various rodent endocrine cell lines, bovine adrenal chromaffin cells, and adrenal medulla. One immunoreactive protein band migrating at the same position as rat brain synapsin Ib was observed mainly in the particulate fractions from alpha TC cells and AtT-20 cells. More than four proteins were detected in both cytosol and particulate fractions from In-R1-G9 cells; one migrated at the same position as synapsin Ib, and properties of other immunoreactive proteins were not clear. Protein bands of lower molecular masses were considered to be degraded products. In bovine adrenal chromaffin cells, the two immunoreactive bands observed around the position of synapsin Ib were exclusively present in the particulate fraction. Two immunoreactive bands were also observed in the particulate fraction when freshly isolated bovine adrenal medulla was examined by immunoblot analysis (Fig. 6B). Synapsin I was observed in the cytosol fractions of alpha TC cells, In-R1-G9 cells, AtT-20 cells, and bovine adrenal medulla. Although small particles are not included in the crude cytosol fraction by the preparation method, the hypotonic conditions would result in the inclusion of the loosely bound proteins of the particulate fraction in the cytosol fraction.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 6.   Synapsin I in various endocrine cells. Crude cytosol (C) and particulate (P) fractions (12 µg of protein each) from mouse glucagonoma alpha TC-6 cells, hamster insulinoma In-R1-G9 cells, mouse anterior pituitary AtT-20 cells, cultured bovine adrenal chromaffin cells (BACC) (A), and freshly obtained bovine adrenal medulla (BAM) (B) were analyzed by Western blot using the polyclonal anti-synapsin I antibody. The entire homogenates of rat brain (2 µg) (A) and MIN6 cells (20 µg) (B) were used as the control. SynI, synapsin I.


    DISCUSSION

When we reported evidence for the existence of synapsin I-like protein in MIN6 cells, the unsolved question was whether or not the protein was a new isoform of synapsin I (13). Although synapsin I was not detected in any significant amount in non-neuronal cells by immunoblots, immunohistochemical, and Northern blot analyses and was considered to be neuron-specific (37, 38), the antibody we used revealed a significant amount of the protein in MIN6 cells. In previous work, the electrophoretic mobility of the protein by SDS-polyacrylamide gel electrophoresis differed from either synapsin Ia or Ib purified from rat brain. These findings raised the possibility that a new isoform of synapsin I was present in MIN6 cells. In attempts at clarification we isolated cDNA clones of the protein from a cDNA library of MIN6 cells. Sequence analyses of the cDNA clones revealed the expression of synapsin I. Compared with rat brain synapsin Ib, 3 additional amino acids (Gln421, Pro422, and Thr601) and substitution of 11 amino acids were observed in synapsin Ib in MIN6 cells. The difference between these amino acids may be because of species specificity and may explain why the synapsin Ib in MIN6 cells migrated at a higher position than did rat synapsin Ib.

Immunoblot analysis of MIN6 cells showed one major band of synapsin I, which was considered to be synapsin Ib, based on the sequence analysis. Another faint band was detected at a slightly higher position than the major band when the autoradiograph was subjected to long exposure to x-ray film. This indicated that synapsin Ia may be expressed in MIN6 cells. We carried out partial sequencing of other clones around the possible splicing site and found that one clone designated as sim2 had the sequence of the synapsin Ia cDNA. These findings suggested that synapsin Ia is a minor isoform in MIN6 cells. This preferential expression of two isoforms was in accord with findings that they are differentially expressed among synapses (29, 39). Functional differences in the synapsin isoforms remain to be elucidated.

Synapsin I has been considered a neuron-specific phosphoprotein, although trace positive immunoreactivity of synapsin I was noted in some endocrine cells by immunoblot, immunohistochemical, and Northern blot analyses (29, 33). The synapsin I gene promoter contained a sequence motif similar to the neuron restrictive silencer element/repressor element-1 (40, 41), and the neuron-specific expression of synapsin I was reported to be under the control of a neuron-specific silencer element and trans-activating factor (42). A zinc finger protein termed neuron restrictive silencer factor (NRSF)/RE-1-silencing transcription factor (REST) was expressed only in non-neuronal cells that bind to this motif and function as a transcriptional repressor (43, 44). It was demonstrated that mRNA coding for NRSF/REST is absent in the insulinoma cell line INS-1 and in three other insulin- and glucagon-producing cell lines (45). In these cells, NRSF/REST activity was absent, and transient expression of NRSF/REST was sufficient to silence a reporter gene containing a NRSF/REST binding site. Our data demonstrated the expression of synapsin I in normal rat islets, endocrine cell lines, and bovine adrenal chromaffin cells and thereby provided further support for the NRSF/REST hypothesis. It would be important to show that REST is absent in MIN6 cells.

We demonstrated the expression of synapsin I in isolated islets from rat pancreas by RT-PCR with RNA from islets (Fig. 4). Because sympathetic and parasympathetic neurons innervate pancreatic islets, there may be contamination of nerve endings in the fraction of isolated islets. However, this is not likely because synapsin I is translated from its mRNA in the cell body and is transported to nerve endings.

In neuronal cells, two types of vesicles have been described; one is synaptic vesicles that contain non-peptide neurotransmitters, and the other is large density core vesicles that contain peptide neurotransmitters. In neuroendocrine and endocrine cells, secretory granules and small synaptic-like vesicles are thought to be counterparts of large dense core vesicles and synaptic vesicles, respectively. In addition to secretory granules, pancreatic beta cells have small synaptic-like vesicles that contain gamma -aminobutyric acid (35). Although synapsin I has been reported to be associated only with synaptic vesicles or synaptic-like microvesicles in rat and bovine neurohypophysis (46), we found that synapsin I was not present in fractions that contained synaptic-like microvesicles, as determined by immunoblot analysis using the anti-synaptophysin antibody but was associated with secretory granules. In agreement with our observation, synaptic-like microvesicles in pinealocytes were not found to interact with synapsin I, as demonstrated immunohistochemically (47). In endocrine and neuroendocrine cells, synapsin I can be absent on synaptic-like microvesicles. In this context, it is important that ribbon synapses in cone, rod, and bipolar cells of the retina with synaptic-like microvesicles do not contain synapsin I (48).

One of the functional roles of synapsin I in neuronal cells was reported to be the regulation of neurotransmitter release (17). Greengard et al. (16) hypothesized that synapsin I forms the link between the vesicle membrane and a primarily actin-based cytoskeleton, thus preventing the vesicles from moving to the presynaptic plasma membrane. The increase in cytosolic Ca2+ levels causes phosphorylation of synapsin I by CaM kinase II, which results in the release of vesicles from the cytoskeletal network and transfer of the vesicles from a resting to an active pool. In pancreatic beta cells, the actin network beneath the plasma membrane may prevent the interaction between secretory granules and plasma membranes (49). By analogy with neuronal cells, synapsin I in beta cells may possibly function as a linker of insulin granules and the cytoskeletal network.

CaM kinases were reported to be present in pancreatic beta cells, including CaM kinase II (8), CaM kinase III (7), and myosin light chain kinase (5). Among these, only CaM kinase II was reported to be present in particulate fractions, which contained insulin secretory granules (7). CaM kinase activity and endogenous substrates have been shown to be present in insulin secretory granules from toadfish (50). Furthermore, in other insulinoma INS-1 cells, the CaM kinase II delta  was seen to be associated with insulin secretory granules (51). We also confirmed the association of CaM kinase II delta  with insulin secretory granules in MIN6 cells by sucrose gradient subcellular fractionation and immunoblot analysis with an antibody specific to CaM kinase II delta  (Fig. 5). Taken together, it is plausible that CaM kinase II is present on the surface of insulin secretory granules. In the present work, we observed that synapsin I co-localizes with secretory granules. In the brain, synapsin I has been reported to be complexed with CaM kinase II alpha  on the synaptic vesicle surface (52). We suggest that synapsin I may be associated with CaM kinase II delta  on insulin secretory granules.

    ACKNOWLEDGEMENTS

We thank Dr. H. Ishihara (Third Department of Internal Medicine, University of Tokyo) for providing the MIN6 cDNAs library, Dr. P. Greengard (Rockefeller University) for providing synapsin Ia and Ib cDNA, Dr. J. Miyazaki (Department of Nutrition and Physiological Chemistry, Osaka University School of Medicine) for providing MIN6 cells, Dr. N. Yanagihara (Department of Pharmacology, University of Occupational and Environmental Health, School of Medicine) for providing polyclonal antibody against rat chromogranin A and for preparation of bovine adrenal chromaffin cells and adrenal medulla, Dr. R. Takaki and Dr. K. Hamaguchi (First Department of Medicine, Oita Medical University) for the In-R1-G9 cells and alpha TC clone 6 cells, Dr. H. Higashida (Department of Biophysics Neuroinformation Research Institute, Kanazawa University School of Medicine) for valuable discussion, and M. Ohara for critical comments on the manuscript.

    FOOTNOTES

* This work was supported in part by grants-in-aid for scientific research from the Ministry of Education, Science, Sports, and Culture of Japan and by a research grant from the Human Frontier Science Program (to H. Y., K. F., and E. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF085809.

parallel To whom correspondence should be addressed: Dept. of Pharmacology, Kumamoto University School of Medicine, 2-2-1 Honjo, Kumamoto 860-0811, Japan. Tel.: 81-96-373-5076; Fax: 81-96-373-5078; E-mail: emiyamot{at}gpo.kumamoto-u.ac.jp.

The abbreviations used are: CaM, calmodulin; CaM kinase, Ca2+/calmodulin-dependent protein kinase; RT, reverse transcriptase; PCR, polymerase chain reaction; NRSF, neuron restrictive silencer factor; REST, RE-1-silencing transcription factor; MES, 2-(N-morpholino) ethanesulfonic acid.

2 Y. Takeuchi, H. Yamamoto, K. Matsumoto, T. Kimura, S. Katsuragi, T. Miyakawa, and E. Miyamoto, J. Neurochem., in press.

    REFERENCES
Top
Abstract
Introduction
References

  1. Prentki, M., and Matshinsky, F. M. (1987) Physiol. Rev. 67, 1185-1248[Free Full Text]
  2. Ashcroft, S. J. H., and Ashcroft, F. M. (1990) Cell. Signalling 2, 197-214[CrossRef][Medline] [Order article via Infotrieve]
  3. Rajan, A. S., Aguillar-Bryan, L., Nelson, D. A., Yaney, G. C., Hsu, W. H., Kunze, D. L., and Boyd, A. E., III (1990) Diabetes Care 13, 340-363[Abstract]
  4. Harrison, D. E., Poje, M., Rocic, B., and Ashcroft, S. J. H. (1986) Biochem. J. 237, 191-196[Medline] [Order article via Infotrieve]
  5. Niki, I., Okazaki, K., Saitoh, M., Niki, A., Niki, H., Tamagawa, T., Iguchi, A., and Hidaka, H. (1993) Biochem. Biophys. Res. Commun. 191, 255-261[CrossRef][Medline] [Order article via Infotrieve]
  6. Landt, M., McDaniel, M. L., Bry, C. G., Kotagal, N., Colca, J. R., Lacy, P. E., and McDonald, J. M. (1982) Arch. Biochem. Biophys. 213, 148-154[Medline] [Order article via Infotrieve]
  7. Hughes, S. J., Smith, H., and Ashcroft, S. J. H. (1993) Biochem. J. 289, 795-800[Medline] [Order article via Infotrieve]
  8. Fukunaga, K., Goto, S., and Miyamoto, E. (1988) J. Neurochem. 51, 1070-1078[Medline] [Order article via Infotrieve]
  9. Wenham, R. M., Landt, M., Walters, S. M., Hidaka, H., and Easom, R. A. (1992) Biochem. Biophys. Res. Commun. 189, 128-133[Medline] [Order article via Infotrieve]
  10. Li, G., Hidaka, H., and Wollheim, C. B. (1992) Mol. Pharmacol. 42, 489-498[Abstract]
  11. Ämmälä, C., Eliasson, L., Bokvist, K., Larsson, O., Ashcroft, F. M., and Rorsman, P. (1993) J. Physiol. (Lond.) 472, 665-688[Abstract]
  12. Wenham, R. M., Landt, M., and Easom, R. A. (1994) J. Biol. Chem. 269, 4947-4952[Abstract/Free Full Text]
  13. Matsumoto, K., Fukunaga, K., Miyazaki, J., Shichiri, M., and Miyamoto, E. (1995) Endocrinology 136, 3784-3793[Abstract]
  14. Easom, R. A., Filler, N. R., Ings, E. M., Tarpley, J., and Landt, M. (1997) Endocrinology 138, 2359-2364[Abstract/Free Full Text]
  15. Ebihara, K., Fukunaga, K., Matsumoto, K., Shichiri, M., and Miyamoto, E. (1996) Endocrinology 137, 5255-5268[Abstract]
  16. Greengard, P., Valtorta, F., Czernik, J., and Benfenati, F. (1993) Science 259, 780-785[Medline] [Order article via Infotrieve]
  17. Südhof, T. C. (1990) J. Biol. Chem. 265, 7849-7852[Abstract/Free Full Text]
  18. Fukunaga, K., Soderling, T. R., and Miyamoto, E. (1992) J. Biol. Chem. 267, 22527-22533[Abstract/Free Full Text]
  19. Yanagihara, N., Oishi, Y., Yamamoto, H., Tsutsui, M., Kondoh, J., Sugiura, T., Miyamoto, E., and Izumi, F. (1996) J. Biol. Chem. 271, 17463-17468[Abstract/Free Full Text]
  20. Miyazaki, J., Araki, K., Yamato, E., Ikegami, H., Asano, T., Shibasaki, Y., Oka, Y., and Yamamura, K. (1990) Endocrinology 127, 126-132[Abstract]
  21. Hamaguchi, K., and Leiter, E. H. (1989) Diabetes 39, 415-425[Abstract]
  22. Moore, H-P. H., Walker, M. D., Lee, F., and Kelly, R. B. (1983) Cell 35, 531-538[Medline] [Order article via Infotrieve]
  23. Takai, R., Ono, J., Nakamura, M., Yokogawa, Y., Kumae, S., Hiraoka, T., Yamaguchi, K., Hamaguchi, K., and Uchida, K. (1986) In Vitro Cell. Dev. Biol. 22, 120-126[Medline] [Order article via Infotrieve]
  24. Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-159[CrossRef][Medline] [Order article via Infotrieve]
  25. Katagiri, H., Terasaki, J., Murata, T., Ishihara, H., Ogihara, T., Inukai, K., Fukushima, Y., Anai, M., Kikuchi, M., Miyazaki, J., Yazaki, Y., and Oka, Y. (1995) J. Biol. Chem. 270, 4963-4966[Abstract/Free Full Text]
  26. Gotoh, M., Maki, T., Kiyoizumi, T., Satomi, S., and Monaco, A. P. (1985) Transplantation 40, 437-438[Medline] [Order article via Infotrieve]
  27. Bergsten, P., Grapengiesser, E., Gylfe, E., Tengholm, A., and Hellman, B. (1994) J. Biol. Chem. 269, 8749-8753[Abstract/Free Full Text]
  28. Pralong, W. F., Bartley, C., and Wollheim, C. B. (1990) EMBO J. 9, 53-60[Abstract]
  29. Südhof, T. C., Czernik, A. J., Kao, H.-T., Takai, K., Johnston, P. A., Horiuchi, A., Kanazir, S. D., Wagner, S. D., Perin, M. S., De Camilli, P., and Greengard, P. (1989) Science 245, 1474-1480[Medline] [Order article via Infotrieve]
  30. Weber, E., Jilling, T., and Kirk, K. L. (1996) J. Biol. Chem. 271, 6963-6971[Abstract/Free Full Text]
  31. Hall, F. L., Mitchell, J. P., and Vulliet, P. R. (1990) J. Biol. Chem. 265, 6944-6948[Abstract/Free Full Text]
  32. Matsubara, M., Kusubata, M., Ishiguro, K., Uchida, T., Titani, K., and Taniguchi, H. (1996) J. Biol. Chem. 271, 21108-21113[Abstract/Free Full Text]
  33. Chin, L-S., Li, L., and Greengard, P. (1994) J. Biol. Chem. 269, 18507-18513[Abstract/Free Full Text]
  34. Jahn, R., and Südhof, T. C. (1994) Annu. Rev. Neurosci. 17, 219-246[CrossRef][Medline] [Order article via Infotrieve]
  35. Reetz, A., Solimena, M., Matteoli, M., Folli, F., Takei, K., and De Camilli, P. (1991) EMBO J. 10, 1275-1284[Abstract]
  36. Winkler, H., and Fischer-Colbrie, R. (1992) Neuroscience 49, 497-528[CrossRef][Medline] [Order article via Infotrieve]
  37. De Camilli, P., Ueda, T., Bloom, F. E., Battenberg, E., and Greengard, P. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 5977-5981[Abstract]
  38. Bloom, F. E., Ueda, T., Battenberg, E., and Greengard, P. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 5982-5986[Abstract]
  39. Mandell, J. W., Czernk, A. J., De Camilli, P., Greengard, P., and Townes-Anderson, E. (1992) J. Neurosci. 12, 1736-1749[Abstract]
  40. Kranar, S. D., Chong, J. A., Tsay, H.-J., and Mandel, G. (1992) Neuron 9, 37-44[Medline] [Order article via Infotrieve]
  41. Li, L., Suzuki, T., Mori, N., and Greengard, P. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1460-1464[Abstract]
  42. Schoch, S., Cibelli, G., and Thiel, G. (1996) J. Biol. Chem. 271, 3317-3323[Abstract/Free Full Text]
  43. Chong, J. A., Tapia-Ramirez, J., Kim, S., Toledo-Aral, J. J., Zheng, Y., Boutros, M. C., Altshuller, Y. M., Frohman, M. A., Kranar, S. D., and Mandel, G. (1995) Cell 80, 949-957[Medline] [Order article via Infotrieve]
  44. Schoenherr, C. J., and Anderson, D. J. (1995) Science 267, 1360-1363[Medline] [Order article via Infotrieve]
  45. Atouf, F., Czernichow, P., and Scharfmann, R. (1997) J. Biol. Chem. 272, 1929-1934[Abstract/Free Full Text]
  46. Navone, F., Di Gioia, G., Jahn, R., Browning, M., Greengard, P., and De Camilli, P. (1989) J. Cell Biol. 109, 3425-3433[Abstract]
  47. Moriyama, Y., and Yamamoto, A. (1995) FEBS Lett. 367, 233-236[CrossRef][Medline] [Order article via Infotrieve]
  48. Koontz, M. A., and Hendrickson, A. E. (1993) Synapse 14, 268-282[Medline] [Order article via Infotrieve]
  49. Orci, L. (1982) Diabetes 31, 538-565[Medline] [Order article via Infotrieve]
  50. Watkins, D. T. (1991) Diabetes 40, 1063-1068[Abstract]
  51. Möhlig, M., Wolter, S., Mayer, P., Lang, J., Osterhoff, M., Horn, P. A., Schatz, H., and Pfeiffer, A. (1997) Endocrinology 138, 2577-2584[Abstract/Free Full Text]
  52. Benfenati, F., Valtorta, F., Rubenstein, J. L., Gorelick, F. S., Greengard, P., and Czernik, A. J. (1992) Nature 359, 417-420[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.